Insider Selling: Vaxcyte, Inc. (NASDAQ:PCVX) Director Sells $531,937.50 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX) Director Teri Loxam sold 6,250 shares of Vaxcyte stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total value of $531,937.50. Following the completion of the transaction, the director now owns 7,175 shares in the company, valued at $610,664.25. This trade represents a 46.55 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Vaxcyte Trading Down 2.9 %

NASDAQ PCVX opened at $85.30 on Monday. The stock has a market cap of $10.63 billion, a P/E ratio of -18.54 and a beta of 0.98. Vaxcyte, Inc. has a 12-month low of $58.10 and a 12-month high of $121.06. The company has a fifty day simple moving average of $88.08 and a two-hundred day simple moving average of $93.67.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.27. During the same period last year, the firm posted ($0.91) EPS. As a group, sell-side analysts forecast that Vaxcyte, Inc. will post -4.14 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on PCVX shares. Needham & Company LLC restated a “buy” rating and issued a $140.00 price target on shares of Vaxcyte in a report on Wednesday, November 6th. The Goldman Sachs Group initiated coverage on shares of Vaxcyte in a research note on Friday, December 20th. They issued a “buy” rating and a $135.00 target price for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a research report on Wednesday, November 6th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, Vaxcyte presently has an average rating of “Buy” and a consensus target price of $145.71.

Institutional Investors Weigh In On Vaxcyte

A number of institutional investors and hedge funds have recently modified their holdings of PCVX. China Universal Asset Management Co. Ltd. raised its position in Vaxcyte by 68.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 21,466 shares of the company’s stock worth $2,453,000 after buying an additional 8,685 shares during the last quarter. Natixis Advisors LLC raised its holdings in shares of Vaxcyte by 61.1% during the third quarter. Natixis Advisors LLC now owns 22,697 shares of the company’s stock worth $2,594,000 after purchasing an additional 8,606 shares during the last quarter. Tri Locum Partners LP purchased a new stake in Vaxcyte in the second quarter valued at $8,559,000. Hsbc Holdings PLC purchased a new stake in Vaxcyte in the second quarter valued at $1,053,000. Finally, Lisanti Capital Growth LLC raised its stake in shares of Vaxcyte by 68.1% during the 3rd quarter. Lisanti Capital Growth LLC now owns 32,515 shares of the company’s stock valued at $3,715,000 after buying an additional 13,175 shares during the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.